Van ECK Associates Corp Purchases 303,395 Shares of Zoetis Inc. $ZTS

Van ECK Associates Corp increased its position in Zoetis Inc. (NYSE:ZTS) by 7.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,252,140 shares of the company’s stock after purchasing an additional 303,395 shares during the quarter. Van ECK Associates Corp’s holdings in Zoetis were worth $305,559,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. J. Stern & Co. LLP lifted its stake in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. State Street Corp lifted its stake in shares of Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after purchasing an additional 149,382 shares during the period. Geode Capital Management LLC boosted its position in shares of Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Zoetis by 5.8% in the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after purchasing an additional 319,709 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 3.2%

Shares of Zoetis stock opened at $77.45 on Friday. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $156.49. The business has a 50-day moving average of $75.57 and a two-hundred day moving average of $95.62. The company has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZTS. Citigroup dropped their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. UBS Group cut their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Barclays lowered their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Finally, William Blair reiterated a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $107.43.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.